Literature DB >> 2578048

Interaction of monoclonal antibodies with MHC class I antigens on mouse spleen cells. II. Levels of expression of H-2K, H-2D, and H-2L in different mouse strains.

S K Dower, D M Segal.   

Abstract

The numbers of MHC class I molecules expressed by spleen cells from various mouse strains were determined by using MHC-specific monoclonal antibodies and a radioactive binding assay. Although small differences were found to exist in some cases, our general conclusion is that different mice of the same strain, congenic mice of different haplotypes, and syngeneic mice of varying background all express similar numbers of class I antigens. B10.A mice (8 to 10 wk old), for example, express 5.3 X 10(4) Kk molecules/cell, 5.4 X 10(4) Dd molecules/cell, and 2.2 X 10(4) Ld molecules/cell. Some of the differences observed in class I antigen expression included: 1) the level of Kk expression increased to a small but significant extent with age in B10.A mice; 2) female B10.A mice expressed slightly higher amounts of Kk than male mice; and 3) B10.A(2R) and B10.A(4R) recombinant strains expressed elevated levels of K-end antigens and slightly decreased levels of D-end antigens when compared with the unrecombinant B10.A strain. In several strains, F1 mice express approximately 50% as many copies of each parental antigen as do the homozygous parents. B10 mice, which are negative for the L antigen, nevertheless express the same total number of D-end molecules as do B10.A mice. The data suggest that the levels of expression of MHC class I molecules are controlled by at least two factors: gene dosage and another factor(s) that gives rise to the small variations in class I antigen expression seen with age, sex, and strain, and to the low expression of Ld relative to Dd and Kk.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578048

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  9 in total

Review 1.  Class I genes and molecules: an update.

Authors:  A M Lew; E P Lillehoj; E P Cowan; W L Maloy; M R van Schravendijk; J E Coligan
Journal:  Immunology       Date:  1986-01       Impact factor: 7.397

2.  Quantitative estimation of HLA-A and HLA-B antigens carrying the Bw4 supertypic specificity in human peripheral blood lymphocytes.

Authors:  J Nosek; E Hinzová; J Vorlíćek
Journal:  Immunogenetics       Date:  1987       Impact factor: 2.846

3.  H-2 class I loci determine sensitivity to MCMV in macrophages and fibroblasts.

Authors:  P Price; A E Gibbons; G R Shellam
Journal:  Immunogenetics       Date:  1990       Impact factor: 2.846

4.  Immunogenicity and tolerogenicity of self-major histocompatibility complex peptides.

Authors:  G Benichou; P A Takizawa; P T Ho; C C Killion; C A Olson; M McMillan; E E Sercarz
Journal:  J Exp Med       Date:  1990-11-01       Impact factor: 14.307

5.  Allospecific cytolytic T lymphocytes recognize conformational determinants on hybrid mouse transplantation antigens.

Authors:  J A Bluestone; M Foo; H Allen; D Segal; R A Flavell
Journal:  J Exp Med       Date:  1985-07-01       Impact factor: 14.307

6.  Distinctive polymorphism at the HLA-C locus: implications for the expression of HLA-C.

Authors:  J Zemmour; P Parham
Journal:  J Exp Med       Date:  1992-10-01       Impact factor: 14.307

7.  Robust In Vitro Pharmacology of Tmod, a Synthetic Dual-Signal Integrator for Cancer Cell Therapy.

Authors:  Diane Manry; Kristian Bolanos; Breanna DiAndreth; Jee-Young Mock; Alexander Kamb
Journal:  Front Immunol       Date:  2022-03-10       Impact factor: 7.561

8.  Cytolytic T cells recognize a chimeric MHC class I antigen expressed in influenza A infected transgenic mice.

Authors:  W A Jefferies; U Rüther; E F Wagner; S Kvist
Journal:  EMBO J       Date:  1988-11       Impact factor: 11.598

9.  Detection and characterization of high affinity plasma membrane receptors for human interleukin 1.

Authors:  S K Dower; S R Kronheim; C J March; P J Conlon; T P Hopp; S Gillis; D L Urdal
Journal:  J Exp Med       Date:  1985-08-01       Impact factor: 14.307

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.